The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study

The interactions between aromatase inhibitors (AI) in breast cancer (BC) and gut microbiota (GM) have not been completely established yet. The aim of the study is to evaluate the bio-diversity of GM and the relationship between GM, inflammation and tumor-infiltrating lymphocytes (TILs) in postmenopausal women with BC during adjuvant AI treatment compared to women with disease relapse during or after one year of AI therapy (“endocrine-resistant”). We conducted a monocenter observational case-control study. Eighty-four women with BC (8 cases, 76 controls) were enrolled from 2019 to 2021. We observed a significant difference in the mean microbial abundance between the two groups for the taxonomic rank of order (p 0.035) and family (p 0.029); specifically, the case group showed higher diversity than the control group. Veillonella reached its maximum abundance in cases (p 0.022). Cytokine levels were compared among the groups created considering the TILs levels. We obtained a statistically significant difference (p 0.045) in IL-17 levels among the groups, with patients with low TILs levels showing a higher median value for IL-17 (0.15 vs. 0.08 pg/mL). Further studies about the bio-diversity in women with BC may lead to the development of new biomarkers and targeted interventions.

[1]  Zhiyong Liang,et al.  Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer , 2022, BMC cancer.

[2]  H. Kwon,et al.  Staphylococcus aureus-Derived Extracellular Vesicles Enhance the Efficacy of Endocrine Therapy in Breast Cancer Cells , 2022, Journal of clinical medicine.

[3]  Z. Soons,et al.  Gut microbiota and short‐chain fatty acid alterations in cachectic cancer patients , 2021, Journal of cachexia, sarcopenia and muscle.

[4]  Jianping Chen,et al.  The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer , 2021, Frontiers in Cell and Developmental Biology.

[5]  Hua You,et al.  Gut microbiota homeostasis restoration may become a novel therapy for breast cancer , 2021, Investigational New Drugs.

[6]  R. Reimer,et al.  The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship , 2020, International journal of molecular sciences.

[7]  E. Alba,et al.  Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment , 2020, Cancers.

[8]  R. Bruno,et al.  COVID-19 and breast cancer: may the microbiome be the issue? , 2020, Future oncology.

[9]  D. Sharma,et al.  Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights , 2020, Cells.

[10]  M. Redinbo,et al.  Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens , 2019, The Journal of Biological Chemistry.

[11]  Paula D. Bos,et al.  Pre-existing commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. , 2019, Cancer research.

[12]  S. Cuschieri.  The STROBE guidelines , 2019, Saudi journal of anaesthesia.

[13]  M. Sang,et al.  Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer , 2019, Oncology letters.

[14]  T. Shien,et al.  Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer , 2018, Oncology letters.

[15]  Qibin Li,et al.  Breast cancer in postmenopausal women is associated with an altered gut metagenome , 2018, Microbiome.

[16]  Juan M. Astorga,et al.  Breast Cancer and Its Relationship with the Microbiota , 2018, International journal of environmental research and public health.

[17]  G. Coppola,et al.  Microbiota effects on cancer: from risks to therapies , 2018, Oncotarget.

[18]  N. Teixeira,et al.  Acquired resistance to aromatase inhibitors: where we stand! , 2018, Endocrine-related cancer.

[19]  C. Sotiriou,et al.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer , 2017, Journal of the National Cancer Institute.

[20]  M. Blaser,et al.  The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. , 2016, Journal of the National Cancer Institute.

[21]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[22]  X. Hua,et al.  Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. , 2015, Journal of the National Cancer Institute.

[23]  F. Antonicelli,et al.  IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells , 2015, Scientific Reports.

[24]  S. Hankinson,et al.  Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers , 2015, Steroids.

[25]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Finlay,et al.  The Intestinal Microbiome in Early Life: Health and Disease , 2014, Front. Immunol..

[27]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Eliaou,et al.  IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2 , 2013, Scientific Reports.

[29]  R. Schwabe,et al.  The Microbiome and Cancer , 2021, Gut Feelings.

[30]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Martin Mozina,et al.  Orange: data mining toolbox in python , 2013, J. Mach. Learn. Res..

[32]  M. Blaser,et al.  Microbiome and malignancy. , 2011, Cell host & microbe.

[33]  Shailesh Singh,et al.  Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression , 2006, BMC Cancer.

[34]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.